Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

被引：0
|
作者：
Boussion, H. [1 ]
Hammel, P. [2 ]
机构：
[1] AERIO, Tokyo, Japan
[2] Hop Beaujon, Clichy, France
来源：
ONCOLOGIE | 2015年 / 17卷 / 1-2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [1] Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
    Caplin, Martyn E.
    Pavel, Marianne
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Martinez, Severine
    Blumberg, Joelle
    Ruszniewski, Philippe
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03): : 224 - 233
  • [2] Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
    Yang, Feng
    Jin, Chen
    Fu, Deliang
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16): : 1556 - 1556
  • [3] Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors
    Barnes, James, I
    Lin, John K.
    Gupta, Divya
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    Kunz, Pamela L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (09): : 1200 - 1209
  • [4] The Cost-Effectiveness of Initial vs Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in the United States
    Barnes, James I.
    Lin, John
    Owens, Douglas K.
    Goldhaber-Fiebert, JeremyD.
    Kunz, Pamela L.
    PANCREAS, 2019, 48 (03) : 429 - 429
  • [5] Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors
    Oziel-Taieb, Sandrine
    Zemmour, Christophe
    Raoul, Jean-Luc
    Mineur, Laurent
    Poizat, Flora
    Charrier, Nathalie
    Piana, Gilles
    Cavaglione, Gerard
    Niccoli, Patricia
    ANTICANCER RESEARCH, 2021, 41 (04) : 2071 - 2078
  • [6] Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors
    Pavel, Marianne E.
    Phan, Alexandria T.
    Wolin, Edward M.
    Mirakhur, Beloo
    Liyanage, Nilani
    Lowenthal, Susan Pitman
    Fisher, George A., Jr.
    Vinik, Aaron I.
    ONCOLOGIST, 2019, 24 (04): : 463 - 474
  • [7] Alternating lanreotide and octreotide in the treatment of metastatic neuroendocrine tumors (NETs)
    Koussis, H.
    Scola, A.
    Cirillo, F.
    Basso, U.
    Ziampiri, S.
    Casara, D.
    Pelizzo, M. R.
    Rebustello, F.
    Behboo, R.
    Jirillo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study
    Wolin, Edward M.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Lombard-Bohas, Catherine
    Liyanage, Nilani
    Thanh, Xuan-Mai Truong
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Investigators, Clarinet
    PANCREAS, 2018, 47 (03) : 358 - 359
  • [9] Antitumor Effects With Lanreotide Autogel/Depot (LAN) in Patients With Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study
    Caplin, Martyn E.
    Phan, Alexandria T.
    Ruszniewski, Philippe
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 351 - 352
  • [10] Natural history of neuroendocrine enteropancreatic tumors
    Mignon, M
    DIGESTION, 2000, 62 : 51 - 58
12345